A phase-2 study of semorinemab (NCT03828747), a humanized monoclonal antibody that binds to the mid-region of tau, showed no significant difference in cognitive decline between the placebo and treatment after 49 weeks. The gene discussed is MAPT; the disease is Mental deterioration.